Lead Product(s) : Brinzolamide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Padagis Announces the Launch of Brinzolamide Ophthalmic Suspension with CGT Exclusivity
Details : Brinzolamide, generic equivalent to the Reference Listed Drug Azopt Ophthalmic Suspension, is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma.
Product Name : Azopt-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2023
Lead Product(s) : Brinzolamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brinzolamide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Teva announced launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 03, 2021
Lead Product(s) : Brinzolamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brinzolamide,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Alcon Inc
Deal Size : $355.0 million
Deal Type : Acquisition
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Details : Simbrinza is a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Product Name : Simbrinza
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 28, 2021
Lead Product(s) : Brinzolamide,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Alcon Inc
Deal Size : $355.0 million
Deal Type : Acquisition
Lead Product(s) : Brimonidine Tartrate,Brinzolamide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.
Product Name : Ailamide
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2020
Lead Product(s) : Brimonidine Tartrate,Brinzolamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
